Doubling THC Doesn't Double the High, New Study Finds

October 25, 2026

Photo by vjkombajn via Pixabay.

A new meta-analysis published October 19, 2026 in Neuroscience & Biobehavioral Reviews is quietly undercutting one of the most repeated assumptions in cannabis policy: that a product's THC percentage tells you roughly how intoxicated it will make you. Researchers Isabella Goodwin of Australian Catholic University and Amir Englund of King's College London pooled data from 41 separate studies covering 1,020 occasional cannabis users, looking specifically at how the subjective high scales with dose. Their answer, in short, is that it doesn't scale the way most people think.

That finding matters well beyond the lab. Lawmakers in multiple states and countries have built THC potency caps, potency-based taxes, and labeling requirements around the premise that double the THC means roughly double the effect, and therefore double the risk. If Goodwin and Englund are right, that premise is shakier than it looks. The real question their work raises isn't just academic: if doubling the THC in a product doesn't double how high someone gets, what exactly are regulators measuring when they cap potency, and what should consumers actually be paying attention to on a label?

What the Study Actually Measured

Photo by sarahjohnson1 via Pixabay.

To make sense of dozens of studies that each used different strains, edibles, vape products, and dosing protocols, Goodwin and Englund first had to solve a measurement problem. Alcohol research long ago settled on the standard drink -- a fixed amount of pure ethanol that lets researchers compare a beer to a glass of wine to a shot of liquor on equal footing. Cannabis research has never had an equivalent, which is part of why potency debates get so muddled. So the authors proposed a Standard THC Unit of 5mg, a benchmark they then used to reanalyze pooled data across the 41 studies.

The participants were specifically occasional users -- people consuming cannabis less than once a week -- which matters because infrequent users haven't built up the tolerance that can blunt or distort subjective effects. After administration, participants rated their experience on a 100-point scale across several dimensions: how high they felt, how anxious, how tired, and how calm. The researchers subtracted out placebo responses to isolate the effect attributable to THC itself.

The numbers for a single 5mg unit were striking in their unevenness. High ratings jumped by 34 points. Anxiety rose by 14 points. Tiredness climbed by 26 points. Calm, by contrast, barely moved, up just 5 points. That spread alone tells you THC doesn't produce one uniform intoxication effect -- it produces several different, only loosely related sensations, each with its own dose-response curve. A standardized unit lets researchers finally compare those curves across studies that otherwise used wildly incompatible products and doses, which is exactly the kind of apples-to-apples comparison cannabis science has lacked.

Doubling the Dose, Not the Effect

Self-reported "high" intensity jumped sharply from placebo to 5mg THC, but only rose modestly further at double the dose (10mg), showing that doubling THC content does not double the subjective high.

The headline result comes from what happened when the dose doubled. Going from one Standard THC Unit (5mg) to two (10mg) pushed the high score from 34 up to just 39 points. That's a 15% increase for a 100% increase in dose -- nowhere close to the linear relationship most people, including many policymakers, assume exists. Anxiety, tiredness, and alertness showed no measurable change at all between the two doses.

Goodwin and Englund describe this as a pharmacological plateau, or ceiling effect, and it's not unique to cannabis. Many drug classes show the same pattern once a receptor system starts to saturate -- the first dose does most of the work, and additional doses produce diminishing returns. The likely mechanism here involves acute tolerance: repeated activation of cannabinoid receptors by THC temporarily reduces the number of receptors available for further stimulation, meaning progressively more THC is required to produce the same subjective bump.

This lines up with a 2024 University of Colorado Boulder study led by Professor Cinnamon Bidwell, which found that people using high-potency concentrates (70-90% THC) ended up about as impaired as people smoking flower in the 16-24% range, despite blood THC levels that differed dramatically between the two groups. Two very different studies, using very different methods, arriving at the same uncomfortable conclusion for potency-based policy: raw THC content is a poor stand-in for how impaired someone actually becomes.

Why This Matters for New and Infrequent Users

Photo via Unsplash.

If there's a group that stands to benefit most from understanding this plateau effect, it's new and infrequent users -- the exact population most likely to misjudge a dose and end up anxious, paranoid, or just unpleasantly overwhelmed. Novices tend to reason by percentage: a product labeled with a higher THC percentage seems like it should hit harder than one labeled lower, so they either underestimate a strong product or overcompensate with a weak one, both with uncomfortable results.

That guesswork is harder than ever given how varied today's market has become. A first-time consumer might encounter flower, vape cartridges, dabs, tinctures, and edibles all in the same dispensary visit, each delivering THC through a different route, at a different speed, with a different onset and duration. A percentage on a label tells you almost nothing about how that product will actually feel once it's absorbed.

What the Goodwin and Englund data suggest is that the high climbs steeply at low doses and then flattens out -- which is really just a scientific rationale for the dosing advice harm-reduction educators have been repeating for years: start low, go slow. A small dose gets you most of the subjective effect; chasing a bigger high with a much bigger dose mostly just adds anxiety and fatigue without adding much actual high.

This advice holds regardless of where you live, but the specifics around it don't. Legal THC potency limits, labeling requirements, and purchase caps vary considerably from state to state and country to country, so it's worth checking your local regulations before assuming a product sold elsewhere would be legal, or dosed the same way, where you are.

What This Means for the THC-Cap Debate

Photo via Unsplash.

The policy backdrop here is significant. A number of states and several countries have floated or already enacted THC potency caps and potency-based tax structures, all resting on the assumption that higher percentage THC translates fairly directly into greater intoxication and greater public health risk. Both this new meta-analysis and Bidwell's 2024 concentrate-versus-flower study chip away at that assumption from different angles, arriving at a similar place: THC percentage alone is a weak predictor of how high someone actually gets.

Goodwin and Englund are careful not to overstate their case. Pooling 41 studies means mixing synthetic and herbal THC, smoking and vaping and oral administration, and a range of different self-report instruments -- all of which introduces noise that a single controlled study wouldn't have. They describe their findings as suggestive rather than definitive, and they've reportedly got a follow-up study planned that would dose the same participants consistently across conditions, which should do a better job confirming whether the plateau effect holds up under tighter experimental control.

Still, the implication for regulators is hard to ignore. If the relationship between THC content and subjective effect flattens out well below the potency levels now common in legal and illicit markets alike, then a regulatory framework built entirely around capping total THC content may be targeting the wrong variable. It might catch some products that pose little additional risk while doing little to address the dosing behaviors -- fast consumption, stacking multiple products, inexperience with a format -- that actually drive bad outcomes.

None of this means potency is meaningless or that a high-THC product is interchangeable with a low-THC one. It means the relationship between dose and effect isn't a straight line -- it climbs fast, then flattens, well before the THC content of many commercial products today would suggest it should. That's a more complicated story than a simple percentage can tell, which is part of why it hasn't shaped policy the way it probably should.

For consumers, the practical takeaway hasn't really changed, it's just better supported now: test your own tolerance at a low dose before assuming a higher-potency label means a proportionally bigger experience. The percentage on the package is a starting point, not a reliable predictor of intensity.

For regulators, this adds to a growing pile of evidence that potency caps are a blunter tool than their proponents assume. Better consumer education around dosing, product format, and tolerance may end up doing more to reduce unwanted outcomes than another round of percentage-based limits -- though that's a harder policy to write, and a much harder one to put on a label.